Introduction
============

Neuroendocrine neoplasms (NEN)s represent a heterogeneous group of neoplasms with distinct morphological and biological manifestations. According to the 2010 WHO classification, NENs are divided into: well differentiated neuroendocrine neoplasm (NEN) G1 (mitotic count \<2 per 10 high power fields (HPF) and/or ≤2% Ki67 index), NEN G2 (mitotic count 2--20 per 10 HPF and/or 3--20% Ki67 index), and poorly differentiated high grade malignant neoplasm (NEC) G3 (mitotic count \>20 per 10 116 HPF and/or \>20% Ki67 index) \[[@B1]\]. Most common sites of origin are the gastrointestinal tract and the bronchopulmonary system. With a global incidence of approximately 5-7 cases per 100,000 per yr, gastroenteropancreatic NEN represents the second most frequent digestive cancer \[[@B2],[@B3]\]. Metastatic involvement of the liver typically develops in about 46--93% of NEN patients \[[@B4],[@B5]\]. In 12.9% of these patients, metastases are already detectable at the time of initial tumor diagnosis and 5-10% of them present with metastases and primary of unknown origin. Up to 75% of patients with small bowel NEN and 30-85% of those with pancreatic NEN present with liver metastases either at initial evaluation or during the course of their disease \[[@B6]-[@B8]\]. Presence and extension of liver metastases are considered important prognostic factors for NENs as they may significantly impair the patient's quality of life because of either tumor bulk or hormonal hypersecretion. Liver metastases can result in a gradual replacement of liver parenchyma resulting in a progressive deficit of function until death, thus decreasing long term survival. Treatment of liver metastases can be curative or palliative. An effective treatment has to result in control of tumor growth and systemic hormonal effect, improvement of quality of life and increase of survival \[[@B9]\]. The treatment of liver metastases should take into account the natural history of the disease, the degree of liver involvement and the severity of related symptoms. The first line treatment of liver metastases is surgery and it can be curative for NEN G1/G2 or palliative. Complete resection (R0/R1) is associated with better long-term survival and quality of life. Resection of NEC G3 is not recommended, but may be considered in individual cases with isolated resecable metastases. Debulking resections (reduction of tumor mass \>90%, resection of metastases and lymphnodes) can exceptionally be justified in palliative situations and incompleted debulking surgery (R2) has limited indication especially in functioning tumors \[[@B10]\]. However, only 10-20% of patients are eligible for either palliative or curative surgical resection. Liver transplantation is a potentially curative approach but limited to extremely selected patients and in experienced centers; moreover risk of recurrence persists in the transplantated liver \[[@B11]\].

For patients with multiple site metastases, systemic therapies are required to control tumor growth and clinical symptoms. They include chemotherapy (with streptozotocin or other agents), biotherapy with somatostatin analogs and/or alpha interferon and therapy with new agents targeting specific molecular pathways \[[@B12]-[@B17]\]. In most of NEN patients with liver metastases, minimally invasive, loco-regional approaches are adopted in place of surgery. They include trans-arterial embolization (TAE), trans-arterial chemoembolization (TACE), radiofrequency thermal ablation. Newly developed locoregional ablative procedures are under evaluation. TAE is based on selective infusion of particles in the branch (segmental or subsegmental) of the hepatic artery supplying the tumor lesions. The goal of TAE is to occlude tumor blood vessels resulting in ischemia and necrosis. TACE differs from TAE for the administration of a chemotherapeutic agent (anthracyclines such as Doxorubicin or Epirobicin) mixed with Lipiodol (fat-soluble contrast-medium with high concentration of Iodine; Lipiodol R), into the hepatic artery followed by the administration of embolizing agents (75-150 μm). In TAE treatment, Lipiodol administration (50%) is followed by the administration of embolizing agents (75-150 μm) without the administration of chemotherapeutic agents. Eligible patients for these procedures include NEN patients in metastatic phase, with predominant liver disease, which is judjed not resectable by surgery \[[@B18],[@B19]\]. Although both techniques have been widely adopted, it remains debatable if the addition of cytotoxic drugs to embolization material increases the effectiveness of bland embolization alone, particularly when performed selectively \[[@B20],[@B21]\]. This review will focus on TAE in NEN patients with liver metastases.

Clinical, biochemical, instrumental characterization of NEN patients before TAE
-------------------------------------------------------------------------------

Clinical work-up has to establish if the tumor is associated with a functioning endocrine syndrome which can result also in life-threatening conditions. Carcinoid syndrome is the most frequent functioning endocrine syndrome predominantly associated with the presence of liver metastases (60%). Regardless from endocrine symptoms, tumor mass-related symptoms need to be carefully evaluated, highlighting in particular the patient performance status, hepatic function and degree of liver involvement by the tumor, as liver metastases are often multilocular and bilateral \[[@B22]\]. Plasma chromogranin A (CgA) should be measured in all cases in order to have a potential sensitive marker, helpful for tumor monitoring and follow-up. However false-positive CgA false positive need to be carefully excluded \[[@B23],[@B24]\]. The 24 h urinary 5-hydroxyindolacetic acid (5-HIAA) is an additional sensitive marker in NENs with carcinoid syndrome \[[@B25]\]. Other helpful NEN markers related to the specific syndrome are insulin, gastrin, glucagons or vasoactive intestinal polypeptide, to be evaluated according to the clinical picture \[[@B26],[@B27]\].

Contrast-enhanced abdominal ultrasound and multidetector-row computed tomography (CT) are the standard initial imaging procedures. Advanced CT protocols and fusioning CT - positron emission tomography (PET) showed a sensitivity of 94--100% \[[@B28],[@B29]\]. As an alternative to CT, magnetic resonance imaging (MRI), using gadolinium as liver-specific contrast agents, is recommended for routine staging, assessment of disease progression and monitoring of the therapy \[[@B30]\]. Functional imaging is mainly based on the \[111-In-diethylene-triamine-penta-acetic-acid (DTPA)-D-Phe1\]-octreotide (Octreoscan). Nowadays this technique has been replaced in several centers with ^68^Ga-radilabelled PET \[[@B31]-[@B33]\]. The diagnostic work-up of liver metastases should encompass tissue acquisition for histopathological and immunohistochemistry examination, since staging of NEN depends on markers of proliferation, such as Ki-67 and mitotic index and evaluation of vascular and neural invasiveness. Tumor staging predicts the prognosis and tailors the therapeutic strategy, particularly in patients who are not candidates for complete resection \[[@B34]\].

Embolization procedures
-----------------------

Hepatic arterial embolization using a percutaneous Seldinger technique under radiological control was developed for metastatic endocrine tumors in the early 1970s. Indications for TAE generally include unresectability with symptoms related to tumor bulk, excessive hormone production, and rapid progression of liver disease. TAE has been shown to improve biophysical markers, palliate symptoms and reduce tumor burden at the radiological evaluation \[[@B20],[@B35]\]. Neuroendocrine liver metastase are higly vascular and receive their blood supply from the hepatic artery (\>90%), while normal liver receives 75-80% of its blood supply from the portal vein. TAE aims to create tumor ischemia embolizing the tumor feeding hepatic arterial branches \[[@B36]\]. Tumor ischemia has already been demonstrated useful in primary hepatocellular carcinoma, and now it finds indication for treatment of neuroendocrine liver metastases. In TACE procedure, tumor tissue ischemia is caused by both the chemotherapy activity and arterial embolization.

Different protocols have been used in TAE and embolizing agents are lipiodol, gel foam particles, polyvinyl alcohol (PVA) particles or microspheres \[[@B37]\]. Eligibility requirements included intact liver and renal function (bilirubin \<2 mg/dL, serum creatinine level \<2 mg/dL). Absolute contraindications were main portal vein occlusion and poor liver function. Other contraindications are: bilirubin greater than 2 mg/dL, hepatic tumor burden greater than 75%, specific contraindications to angiography such as allergy o contrast medium, fever and/or septic state, renal insufficiency, peripheral vascular disease, coagulopathies \[[@B38]\]. All patients were admitted to the hospital prior to the procedure and started intravenous hydration. Prior to embolization, a celiac angiogram was performed to identify the hepatic vasculature and ensure patency of the portal vein. Superior mesenteric artery angiogram was performed if needed to evaluate for accessory or replaced hepatic arteries supplying the liver. Embolization was performed until the selected vessel demonstrates complete or near complete stasis of flow. Usually the liver lobe with the bulkiest disease was embolized first. After embolization, patients were monitored in the hospital and discharged only after their liver enzymes had peaked. All patients were prophylactically administered antibiotics for one week in order to prevent abscess formation. Intravenous narcotics were typically administered for pain control. In case of recurrence or progression, TAE procedure can be performed several times \[[@B39]\]. When proximal embolization of tumor-feeding arteries in hepatic metastases was performed major effectiveness is remarked. Individual embolizations were spaced approximately 4 weeks apart and the majority of patients completed their embolizations in 2 or 3 times \[[@B9],[@B40],[@B41]\].

Efficacy
--------

Many reviews have been published on loco-regional ablative treatments of liver metastases of NENs. Several studies have been reported on TACE, while only few studies on TAE. This review focuses on TAE performance and safety in patients with liver metastases of NENs. It has to be highlighted that many authors did not report data on clinical response to TAE or reported these data as indirect consequence of decrease of tumour markers.

As a whole, 896 patients with NEN and liver metastases have been treated for a total of 979 TAE procedures. Median survival rates ranged from 10 to 80 months \[[@B9],[@B21],[@B35],[@B39],[@B42]-[@B52]\], but in the most of studies it was between 35 and 60 months (Table  [1](#T1){ref-type="table"}). Survival was reported to be correlated to objective tumor response. Progression free survival ranged from 0 to 60 months. Objective tumour response, including partial and complete response, was 50% as average (range, 2-100%). If we consider both tumour response and stabilization of tumor growth, the rate of patients who received a benefit from TAE was about 40% \[[@B9],[@B21],[@B35],[@B39],[@B42]-[@B52]\] (Table  [1](#T1){ref-type="table"}). Clinical response was about 56% (range, 9-100%). As far as biochemical response is concerned, TAE was reported to be effective in reducing biochemical markers in \>50% of patients with NEN. In NEN patients with carcinoid syndrome, major decreases in 5-HIAA levels (\>50% decrease as compared to baseline) occured in a range of 11-100% \[[@B9],[@B35],[@B39],[@B42]-[@B44],[@B51],[@B53]-[@B57]\] (Table  [2](#T2){ref-type="table"}).

###### 

Tumour response and survival rate in patients treated with Transarterial Embolization (TAE)

                 **Paper**                              **Number and type of NEN**                 **Number of TAEs**                               **TR**                                       **OS**
  --------------------------------------- ------------------------------------------------------- -------------------- ---------------------------------------------------------------- ------------------------
      **Loewe et al. 2003**\[[@B7]\]                           23 carcinoids                             75 TAE                      4 (18%) CR, 12 (55%) PR, 6 (27%) PD                       69 months
                                                            (22 pts evaluable)                                                                                                          
      **Gupta et al. 2003**\[[@B18]\]                          69 carcinoids                          Carcinoids:       Carcinoids: 46 (67%) PR, 6 (8.5%) MR, 11 (16%) SD, 6 (8.5%) PD         18 months
                                                                 54 PNENs                            42 TAE/27 TACE          PNEN: 19 (35%) PR, 1 (2%) MR, 32 (59%) SD, 2 (4%) PD                   
                                                                  PNENs:                                                                                                                
                                                              32 TAE/22 TACE                                                                                                            
    **Carrasco et al. 1986**\[[@B32]\]                         25 carcinoids                             25 TAE                             20 (87%) CR, 1 (5%) PD                             11 months
                                                              (23 evaluable)                                                                                                            
    **Strosberg et al. 2006**\[[@B36]\]                        59 carcinoids                            161 TAE                   23 pts evaluable: 11 (48%) PR, 12 (52%) SD                   36 months
                                                                 20 PNENs                                                                                                               
                                                            5 unspecified NENs                                                                                                          
     **Hanssen et al. 1989**\[[@B39]\]                  19 carcinoids (7 evaluable)                      7 TAE                                   7 (100%) PR                                   12 months
    **Wangberg et al. 1996**\[[@B40]\]                         64 carcinoids                             40 TAE                                     \-\--                                      60 months
    **Eriksson et al. 1998**\[[@B41]\]                         29 carcinoids                             55 TAE                 Carcinoids: 18 (62%) CR, 9 (31%) SD, 2 (7%) PD           80 months (carcinoids)
                                                                 12 PNENs                                                          PNEN: 6 (67%) CR, 1 (11%) SD, 2 (22%) PD                 20 months (PNEN)
      **Brown et al. 1999**\[[@B42]\]                          21 carcinoids                             63 TAE                                     \-\--                                      60 months
                                                                 14 PNENs                                                                                                               
   **Chamberlain et al. 2000**\[[@B43]\]                       41 carcinoids                             59 TAE                         33 pts evaluable: 19 (58%) SD                              NR
                                                                 44 PNENs                                                                                                               
   **Ruutiainen et al. 2007**\[[@B44]\]                     67 unspecified NENs                      23 TAE/44 TACE                               (100%) CR                                    36 months
                                                             (219 procedures)                           (35%) CR                                                                        
       **Ho et al. 2007**\[[@B45]\]                            31 carcinoids                         7 TAE/86 TACE                            33 pts evaluable:                                48 months
                                                                  15 PNEN                                                Carcinoids: 5 (23%) PR, 5 (23%) MR, 7 (31%) SD, 5 (23%) PD\*               
                                           PNEN: 2 (18%) PR, 3 (27%) MR, 5 (46%) SD, 1 (9%) PD\*                                                                                        
      **Kamat et al. 2008**\[[@B46]\]                       60 unspecified NENs                      33 TAE/27 TACE           12 (25%) PR, 6 (12%) MR, 22 (46%) SD, 8 (17%) PD\*               9.3 months
                                                             (123 procedures)                       48 pts evaluable                                                                    
      **Pitt et al. 2008**\[[@B47]\]                       100 unspecified NENs                     106 TAE/123 TACE                                \-\--                                     32.4 months
      **Sward et al. 2009**\[[@B48]\]                         107 carcinoids                            213 TAE                                     \-\--                                      56 months
      **Fiore et al. 2014**\[[@B50]\]                            12 PNENs                            38 TAE/37 TACE                           17 pts evaluable:                                60 months
                                                               16 NENs ileum                                                               12 (70%) CR, 5 (30%) PR                                  
                                                               2 NENs colon                                                                                                             

Legend = PNEN: NEN pancreas, TR: tumor response, OS: overall survival, PR: partial response, CR: complete response, MR: minor response, SD: stable disease, PD: progressive disease, NR: not reached, \*cumulative results.

###### 

Symptomatic and biochemical response in patients treated with TAE

                 **Paper**                     **Number and type of NEN**             **Number of TAEs**                                   **BR**                                 **SR (endocrine symptoms)**           **SR (aspecific symptoms)**
  --------------------------------------- ------------------------------------ --------------------------------- ---------------------------------------------------------- --------------------------------------- -----------------------------------
      **Loewe et al. 2003**\[[@B7]\]              23 small-bowel NENs                         75                          13 pts evaluable: 8 (61%) PR, 5 (39%) MR                     9 pts evaluable:                            - - -
                                               Abdominal pain 5 (56%) PR                                                                                                                                            
                                                  Diarrhea 2 (22%) CR                                                                                                                                               
                                                  Flushing 2 (22%) CR                                                                                                                                               
      **Gupta et al. 2003**\[[@B18]\]                69 carcinoids                        Carcinoids:                                      - - -                                             - - -                                 - - -
                                                     42 TAE/27 TACE                                                                                                                                                 
                                                        54 PNENs                            PNENs:                                                                                                                  
                                                     32 TAE/22 TACE                                                                                                                                                 
    **Carrasco et al. 1986**\[[@B32]\]               25 carcinoids                            25                                        18 (72%) CR                                          - - -                              20 (87%) CR
    **Strosberg et al. 2006**\[[@B36]\]              59 carcinoids                            161                                    35 pts evaluable:                       Flushing and/or diarrhea 21 (48%) CR               9 (20%) CR
                                                        20 PNENs                                                                        28 (80%) CR                               Abdominal pain 11 (25%) CR                (44 pts evaluable)
                                                   5 unspecified NENs                                                                    4 (11%) MR                                 Hypoglicemia 3 (7%) CR                            
                                                   3 (9%) no response                 (44 pts evaluable)                                                                                                            
     **Hanssen et al. 1989**\[[@B39]\]      19 carcinoids (7 pts evaluable)                    7                                        7 (100%) PR                          Diarrhea and/or flushing: 7 (100%) CR                 - - -
    **Wangberg et al. 1996**\[[@B40]\]               64 carcinoids                            40                                        40 (100%) PR                                         - - -                             40 (100%) PR
                                                   (40 pts evaluable)                                                                                                                                               
    **Eriksson et al. 1998**\[[@B41]\]               29 carcinoids                            55                  Carcinoids: 12 (41%) PR, 8 (28%) MR, 9 (31%) no response                   - - -                         11 carcinoid (38%) CR
                                                        12 PNENs                                                     PNEN: 6 (50%) PR, 2 (16%) MR, 4 (34%) no response                                                        6 PNEN (50%) CR
      **Brown et al. 1999**\[[@B42]\]                21 carcinoids                            63                                           - - -                                             - - -                              46 (96%) PR
                                                        14 PNENs                        (48 evaluable)                                                                                (48 TAE evaluable)            
   **Chamberlain et al. 2000**\[[@B43]\]             41 carcinoids                            59                                           - - -                                       33 pts evaluable                         31 (94%) PR
                                                26 non functional PNENs                                                        Hormonal and/or pain symptoms                                                        
                                                  18 functional PNENs                                                                   31 (94%) PR                                                                 
   **Ruutiainen et al. 2007**\[[@B44]\]           67 unspecified NENs           23 TAE/44 TACE (219 procedures)                            - - -                                             - - -                                 - - -
       **Ho et al. 2007**\[[@B45]\]                     46 NENs                          7TAE/86 TACE                                      - - -                                             - - -                           27 pts evaluable
                                                (31 carcinoids; 15 PNEN)                                                                21 (78%) PR                                                                 
      **Kamat et al. 2008**\[[@B46]\]             60 unspecified NENs                   33 TAE/27 TACE                                     - - -                                             - - -                           20 pts evaluable
                                                    (123 procedures)                                                                    13 (65%) PR                                                                 
      **Pitt et al. 2008**\[[@B47]\]              100 unspecified NENs                  106TAE/123TACE                                     - - -                                             - - -                   35 pts evaluable: 29 TAE (83%) PR
                                           35 pts evaluable: 32 TACE (86%) PR                                                                                                                                       
      **Sward et al. 2009**\[[@B48]\]                107 carcinoids                           213                                    37 pts evaluable:                       Diarrhea and/or flushing 76 (71%) CR                76 (71%)
                                                    CgA: 19 (51%) CR                                                                                                                                                
                                                   54 pts evaluable:                                                                                                                                                
                                                   5HIAA: 26 (48%) CR                                                                                                                                               
     **Fiore et al. 22014**\[[@B50]\]                   12 PNENs                        38 TAE/37 TACE                                     - - -                                             - - -                           19 pts evaluable
                                                     16 NENs ileum                                                                       (64%) PR\*                                                                 
                                                      2 NENs colon                                                                                                                                                  

Legend = PNEN: NEN pancreas, BR: biochemical response, SR: symptomatic response, PR: partial response, CR: complete response, MR: minor response.

\*Cumulative results.

The first study reporting on TAE treatment in patients with liver metastases from NEN was published by Carrasco et al. \[[@B35]\]. A response to TAE was observed in 95% of patients with malignat liver metastases from carcinoids, with a median response duration of 11 months. Tumour response was subsequently confirmed in all studies performed on TAE and the rate of patients responsive to treatment (objective response plus stability) was always about or more than 80% and the median reponse duration was about 36 months \[[@B9],[@B21],[@B39],[@B47]-[@B49],[@B52]\] (Table  [1](#T1){ref-type="table"}).

In the Carrasco study, a symptomatic response occurred in 87% of patients and correlated with size decrease of liver lesions. In the Fiore study a symptomatic response occurred in 64% of patients who had an uncontrolled endocrine syndrome \[[@B52]\]. Furthermore, a decrease in urine 5-HIAA concentrations of about 41% as average has been reported \[[@B35]\]. A similar o greater effect on 5-HIAA was confirmed in subsequent studies \[[@B9],[@B35],[@B39],[@B42],[@B43],[@B51],[@B52]\] (Table  [2](#T2){ref-type="table"}). When combined with somatostatin analogs or interferon therapy, TAE was found to be still more effective in reducing 5-HIAA and controlling carcinoid syndrome \[[@B42],[@B43]\] (Table  [2](#T2){ref-type="table"}). The biochemical response to repeated TAE cycles was similar to that observed after the first cycle. Finally, the biochemical response was also found to be correlated with survival \[[@B51]\] (Table  [2](#T2){ref-type="table"}).

Some studies reported a comparison between carcinoid tumors (according to old classifications of NEN) and pancreatic NENs. Eriksson et al. reported a median survival of 80 months in patients with midgut carcinoid tumors and 20 months in those with pancreatic NENs \[[@B42]\] (Table  [1](#T1){ref-type="table"}). Similar difference was reported in the Gupta study where progression free survival as well as tumor response rate were higher in carcinoids than in pNENs \[[@B21]\]. On the contrary, no difference in overall survival, progression free survival and objective response was reported by Ho et al. \[[@B48]\] (Table  [1](#T1){ref-type="table"}).

On the other hand, symptomatic response and duration of the response were similar for patients with carcinoid tumors and pancreatic NEN \[[@B21],[@B35],[@B42]-[@B46],[@B48],[@B51],[@B52]\] (Table  [2](#T2){ref-type="table"}). In general, the duration of response was longer in patients treated for hormonal symptoms with or without pain, while it was shorter when the indication was pain alone \[[@B45]\] (Table  [2](#T2){ref-type="table"}).

Safety
------

TAE was found to be a quite safe procedure. Range of TAE-related death was from 2 to 13 patients, with a total of 50 deaths. Adverse events such as ischemia of biliary tree, post-embolization syndrome may occur. Complications were observed in a total of 125 patients (14%) of all 896 patients with NENs, but it is not always clarified wether adverse events and toxicity occurred after TAE and/or TACE (Table  [3](#T3){ref-type="table"}). Post-embolization syndrome includes abdominal pain, nausea, fevers, hypertension, thrombocytopenia, leukocytosis, transient increase in liver enzymes (predominantly transaminases) and LDH which generally comes down within a few days to 2-3 weeks. Increased bilirubin levels have also been noted. Ischemia of the biliary tree has also been rarely reported and moderate elevation of alkaline phosphatase. When some devices were considered to keep the patient well hydrated and in supportive care, post-embolization syndrome resulted to be less frequent \[[@B4],[@B44]\]. As a whole, TAE may be considered a quite safe procedure, given the high number of procedures carried out (979) and the low number of deaths (50 patients: 6%) and complications (125 patients: 14%) (Table  [3](#T3){ref-type="table"}).

###### 

Safety of TAE

                 **Paper**                                **Number and type of NEN**                   **Number of TAE**                                                      **Complications**                                                                             **Death**
  --------------------------------------- ----------------------------------------------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------
      **Loewe et al. 2003**\[[@B7]\]                          23 small-bowel NENs                             75                                                        Decreased body weight 1 (1%)                                                                         2 (8%)
                                                                Leg pain 1 (1%)                                                                                                                                                                     
      **Gupta et al. 2003**\[[@B18]\]                            69 carcinoids                            Carcinoids:                                                 Serious adverse events 19 (15%)\*                                                                      1 (1%)
                                                                   54 PNENs                             42 TAE/27 TACE                                                                                                                              
                                                                    PNENs:                                                                                                                                                                          
                                                                32 TAE/22 TACE                                                                                                                                                                      
    **Carrasco et al. 1986**\[[@B32]\]                           25 carcinoids                                25                                                                    - - -                                                                                    2 (8%)
                                                                (23 evaluable)                                                                                                                                                                      
    **Strosberg et al. 2006**\[[@B36]\]                          59 carcinoids                                161                                                                   - - -                                                                                    2 (2%)
                                                                   20 PNENs                                                                                                                                                                         
                                                              5 unspecified NENs                                                                                                                                                                    
     **Hanssen et al. 1989**\[[@B39]\]                           19 carcinoids                                 7                                                                    - - -                                                                                     - - -
                                                                 (7 evaluable)                                                                                                                                                                      
    **Wangberg et al. 1996**\[[@B40]\]                           64 carcinoids                                40                                                                    - - -                                                            Increased risk of cardiovascular deaths (not specified)
    **Eriksson et al. 1998**\[[@B41]\]                           29 carcinoids                                55                                                  Unspecified severe complications 6 (10%)                                                                  13 (31%)
                                                                   12 PNENs                                                                                                                                                                         
      **Brown et al. 1999**\[[@B42]\]                            21 carcinoids                                63                                                  Unspecified severe complications 11 (17%)                                                                  4 (6%)
                                                                   14 PNENs                                                                                                                                                                         
   **Chamberlain et al. 2000**\[[@B43]\]                         41 carcinoids                                59                                                                    - - -                                                                                    4 (6%)
                                                            26 non functional PNENs                                                                                                                                                                 
                                                              18 functional PNENs                                                                                                                                                                   
   **Ruutiainen et al. 2007**\[[@B44]\]                       67 unspecified NENs                       23 TAE/44 TACE                                                 Unspecified toxicity 34 (50%)\*                                                                    \(1\) 1.4%\*
                                                               (219 procedures)                                                                                                                                                                     
       **Ho et al. 2007**\[[@B45]\]                                 46 NENs                              7 TAE/86 TACE                                               Unspecified complications 9 (10%)\*                                                                    4 (4.3%)
                                                           (31 carcinoids; 15 PNEN)                                                                                                                                                                 
      **Kamat et al. 2008**\[[@B46]\]                         60 unspecified NENs                       33 TAE/27 TACE                                              Unspecified complications 21 (35%)\*                                                                    12 (20%)
                                                               (123 procedures)                                                                                                                                                                     
      **Pitt et al. 2008**\[[@B47]\]                         100 unspecified NENs                       106TAE/123TACE     Liver abscesses, ileus, groin hematoma, hypotension 7 (13%) TAE hematoma, acute renal failure, and a biloma 3 (6%) TACE                          3 (3%)\*
      **Sward et al. 2009**\[[@B48]\]                           107 carcinoids                                213                                                           Liver abscess 4 (4%)                                                                             2 (2%)
                                                           Mild pancreatitis 1 (1%)                                                                                                                                                                 
                                           Accidental occlusions of the common hepatic artery 2 (2%)                                                                                                                                                
      **Fiore et al. 2014**\[[@B50]\]                              12 PNENs                             38 TAE/37 TACE                                             Post-embolization syndrome 6 (40%) TAE                                                                      0%
                                                                 16 NENs ileum                                                                                     Post-embolization syndrome 8 (60%) TACE                                                                       
                                                                 2 NENs colon                                                                                                                                                                       

\*Cumulative results.

Conclusions
===========

TAE appears to be an optimal treatment approach for inoperable liver metastases from NENs, for higher metastatic load, for management of symptoms alone and in association with interferon or somatostatin analogues, suggesting a prolonged 5-yr survival and local tumor control and for survival improvement \[[@B42],[@B43],[@B45],[@B51]\]. Tumor response as well as survival, but not clinical and biochemical response, appear to be better for patients with carcinoid than pancreatic NENs.

TAE is considered a safe procedure. The low number of complications during and/or after TAE procedures can be easily and quickly treated, while the small number of deaths further confirms the safety of this technique. Moreover the deaths are often associated with adverse effects not related to TAE, but with the chemotherapeutic agents used for TACE. It is essential that TAE is performed by highly qualified and specialized team. Finally, the presence of extra-hepatic metastases or unresected primary tumor should not limit the use of TAE \[[@B48]\] since the liver function plays the most important role in the survival of these patients.

On the other hand, TAE should be avoided in patients with massive tumor burden and severely compromised liver function, poor performance status, sepsis, carcinoid heart disease and other risk factors for treatment related mortality (Table  [4](#T4){ref-type="table"}). In these cases less aggressive TAE, repeated if needed, can be effective, while decreasing the risk for procedure related mortality \[[@B49],[@B50]\].

###### 

Indications and contraindications of TAE in patients with NENs

  **Indications**                                                          **Contraindications**
  ------------------------------------------------------------------------ -----------------------------------------------------------------------------------
  \- NEN tumor functioning or not                                          \- Massive tumor burden
  \- Highly vascularised liver metastases                                  \- Severely compromised liver function
  \- Liver metastases \>3 in number and or \>3 cm in size                  \- Poor performance status
  \- Sepsis                                                                
  \- Patients with tumor mass-related symptoms and/or carcinoid syndrome   \- Carcinoid heart disease and other risk factors for treatment related mortality

Future randomized, prospective clinical trials comparing safety, efficacy and lorng term outcomes of different treatment approaches for liver metastases in NEN patients with comparable disease, should better define the role of TAE. In conclusion, available data suggest TAE as a safe therapeutic option in patiens with liver metastases from NENs, effective for controlling tumor progression and improving mass and endocrine symptoms, while increasing long term survival. In order to minimize risk related procedure TAE should be performed in a multidisciplinary setting and in experienced NEN centers. Finally, the choice of TAE instead of TACE, PRRT, chemotherapy or biotherapy should be performed in a multidisciplinary setting and in experienced NEN centers, according to patient and tumor characteristics.
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